Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Meet the Expert: Daniel Seymour

Share :
Published: 1 Jul 2020
Views: 478
Rating:
Save
Daniel Seymour - BIO Ventures for Global Health, Seattle, USA

Following on from the webinar 'AC3T - Assessing, profiling, and building cancer clinical trial capacity in Africa' (hosted by the African Clinical Trials Consortium), in this Meet the Expert session Daniel Seymour answers submitted questions moderated by Prof Folakemi Odedina.

Watch Daniel Seymour's webinar here.

Find other sessions from the series here.

Related Videos

Tele-mentoring: Impact of project ECHO
Dr Sanjeev Arora - Project ECHO, Albuquerque, USA
Tele-mentoring: Impact of project ECHO ( Dr Sanjeev Arora - Project ECHO, Albuquerque, USA )
22 Oct 2024
Choosing Wisely in pathology
Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
18 May 2023
Choosing Wisely in radiology Tanzania
Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
18 May 2023
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast...
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, German )
2 May 2023
The use of IORT at Universitätsmedizin Mannheim hospital
Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany
The use of IORT at Universitätsmedizin Mannheim hospital ( Dr Elena Sperk - Universitätsmedizin Mannheim, Mannheim, Germany )
2 May 2023
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...
Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA
Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )
25 Apr 2023
Why tumour markers are not recommended as screening tests
Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines
Why tumour markers are not recommended as screening tests ( Dr Frederic Ting - Riverside Medical Center, Bacolod, Philippines )
20 Apr 2023
Choosing Wisely to mitigate financial toxicity in cancer care in Africa
Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania
Choosing Wisely to mitigate financial toxicity in cancer care in Africa ( Dr Penina Mnandi - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )
22 Mar 2023
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...
Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )
22 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation